Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30 participants
OBSERVATIONAL
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Postoperative Bleeding Prevention in Massive Bone Tumour Resection
NCT02153593
Prevention of Intraoperative Bleeding and Postoperative Swelling in Orthognathic Surgery Through the Use of Tranexamic Acid
NCT02229292
Topical Application of Tranexamic Acid and Postoperative Blood Loss in Femoral Neck Fractures
NCT01727843
Prevention of Postoperative Bleeding in Subcapital Femoral Fractures
NCT02150720
Effect of Perioperative Tranexamic Acid on Blood Loss During Management of Maxillofacial Trauma
NCT04494126
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The software defines the quantity of thrombin generated (nM) according to time (in minute) and calculate the values of:
* Lag time: latent period before the beginning of synthesis of thrombin.
* Start Tail: duration of the process.
* Peak: peak of thrombin, is the maximal rate of generated thrombin.
* ETP (Endogenous Thrombin Potential): area under the curve representing the total potential of generation of thrombin.
* Time to Peak: time required to reach the peak of thrombin. It is these values which will serve as criteria of evaluation for our study.
Osseous type
The cancellous bone is majority in the short bones and the epiphyses of the long bones. It is crisp, constituted by fine osseous patches arranged in a not concentric way around wide open cavities, filled with bone marrow rich in cells, and richly vascularized. The cancellous bone is surrounded with compact bone. At the level of tooth sockets, this osseous type is found in particular at the level of interradicular septa.
The compact bone establishes the cortical. It is dense, consisted of systems of Havers. Every system is formed by a reduced central channel containing some vascularized connective tissue, and thick, concentric osseous small strips, in and between which prepares ostéocytes. This osseous type is situated at the alveolar level in the external part.
Inhibitors
To verify the possible ways involved in the thrombin formation, the investigators shall use specific inhibitors of these likely ways of activation:
* An inhibitor of the extrinsic way of the coagulation: an antibody anti tissue factor.
* An inhibitor of the intrinsic way of the coagulation: the bovine aprotinin.
* An inhibitor of phospholipids: the annexin V. Methodology of the Research
Plan of investigation
* Information of the eligible patients for the study (patients requiring dental extractions with bone removal) concerning the methods and the objectives of the research by means of the information note.
* If the patient agrees to participate in the study, realization of osseous takings and conditioning of the osseous takings for freezing in the liquid nitrogen.
* Put in touch by the osseous takings with some plasma (from pools of plasma used in laboratory for the calibration of the various automatous) and measure of the genesis of thrombin by thrombinography.
To make this measure, the osseous fragments will be put down at the bottom of the wells of the microplate then 10µL of buffer HBS will be added. The fragmentation of the osseous takings will be realized by means of a sterile material and by limiting the time of manipulation except environment.
Every sample will be handled triplicate there. Two wells will be dedicated to the standard thrombin (20µL). Two controls will be used: - positive control: 10µL of tissue factor, in the concentration of 1 or 5 pM and 10µL of PPL in the dilution of 1/100 will be used.
\- Negative control: 20µL of physiological salt solution will be used. Eighty microliters of plasma are going to be put down in each of the wells. Fifty microliters of fluorescent substratum will be added to the mixture buffer - substratum fluorogenic beforehand prepared and the device is going to distribute 20µL some mixture in each of the wells, thus containing in the end 120µL.
The measures were made every 20 seconds during 60 minutes by the Fluoroskan Ascent Reader. The Thrombinoscope softwar® (Version 3.0.0.29, Maastricht) converts the intensity of fluorescence nM of thrombin according to the time.
The results of the measures will be grouped in cancellous bone, compact bone, control FT1pM, control FT5pM and secondarily averaged.
According to the obtained results, samples (compact and\\or cancellous) positive for the genesis of thrombin will be analyzed in the presence of specific inhibitors of the various possible ways of activation of the coagulation. Calibrations will be made to choose the most appropriate concentration in inhibitors.
Logistics of the study
An information concerning the objectives and the modalities of the study will be given to every patient benefiting from one or several dental extractions with bone removal. If the patient agrees to participate in the study (oral agreement), the osseous taking, associated automatically with the dental extraction will be kept.
After taking, the osseous fragments will be immersed in a solution of cryopreservation beforehand prepared, then put down in a freezer in -70°C during a minimum of 24 hours before being immersed in the liquid nitrogen.
The measures of trhombinography will be realized at the rate of an analysis every other week, adaptable periodicity according to the number of recruitment made during the period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
bone donors
bone removal
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bone removal
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patients requiring dental extractions with bone removal
* The patients agreeing to participate in the search
Exclusions criteria
Will not be included in this study:
* Minor patients.
* Patients protected by the law.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CHU de Reims
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Reims
France, Reims, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PJ12077
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.